GLP-1 drugs showGLP-1 drugs show potential against many cancers
Studies presented at the American Society of Clinical Oncology meeting in Chicago found that patients taking GLP-1 drugs had lower risks of cancer, slower disease progression, better survival, and improved responses to some treatments.
The findings, reported on June 3, 2026, suggest these diabetes and weight-loss medicines could have wider medical uses, although researchers still need more evidence before changing care.
If confirmed, the results could influence cancer treatment research and how these drugs are studied around the world.
- ASCO meetings often draw thousands of oncologists, making them a major venue for early research results.
- GLP-1 medicines were first developed for diabetes before becoming widely used for weight management.
- Cancer researchers often look for unexpected drug effects because existing medicines can sometimes be repurposed faster than new ones.
